Elizabeth B Harstad1, Amy L Weaver2, Slavica K Katusic3, Robert C Colligan4, Seema Kumar5, Eugenia Chan1, Robert G Voigt6, William J Barbaresi7. 1. Division of Developmental Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; 2. Departments of Health Sciences Research. 3. Departments of Health Sciences Research, william.barbaresi@childrens.harvard.edu slavica.katusic@mayo.edu. 4. Psychiatry and Psychology, and. 5. Pediatrics, Mayo Clinic, Rochester, Minnesota; and. 6. Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. 7. Division of Developmental Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; william.barbaresi@childrens.harvard.edu slavica.katusic@mayo.edu.
Abstract
BACKGROUND AND OBJECTIVE: There is ongoing concern that stimulant medications may adversely affect growth. In a sample of attention-deficit/hyperactivity disorder (ADHD) cases and controls from a population-based birth cohort, we assessed growth and the association between stimulant treatment and growth. METHODS: Subjects included childhood ADHD cases (N = 340) and controls (N = 680) from a 1976 to 1982 birth cohort (N = 5718). Height and stimulant treatment information were abstracted from medical records and obtained during a prospective, adult follow-up study. For each subject, a parametric penalized spline smoothing method modeled height over time, and the corresponding height velocity was calculated as the first derivative. Peak height velocity (PHV) age and magnitude were estimated from the velocity curves. Among stimulant-treated ADHD cases, we analyzed height Z scores at the beginning, at the end, and 24 months after the end of treatment. RESULTS: Neither ADHD itself nor treatment with stimulants was associated with differences in magnitude of PHV or final adult height. Among boys treated with stimulants, there was a positive correlation between duration of stimulant usage before PHV and age at PHV (r = 0.21, P = .01). There was no significant correlation between duration of treatment and change in height Z scores (r = -0.08 for beginning vs end change, r = 0.01 for end vs 24 months later change). Among the 59 ADHD cases treated for ≥3 years, there was a clinically insignificant decrease in mean Z score from beginning (0.48) to end (0.33) of treatment (P = .06). CONCLUSIONS: Our findings suggest that ADHD treatment with stimulant medication is not associated with differences in adult height or significant changes in growth.
BACKGROUND AND OBJECTIVE: There is ongoing concern that stimulant medications may adversely affect growth. In a sample of attention-deficit/hyperactivity disorder (ADHD) cases and controls from a population-based birth cohort, we assessed growth and the association between stimulant treatment and growth. METHODS: Subjects included childhood ADHD cases (N = 340) and controls (N = 680) from a 1976 to 1982 birth cohort (N = 5718). Height and stimulant treatment information were abstracted from medical records and obtained during a prospective, adult follow-up study. For each subject, a parametric penalized spline smoothing method modeled height over time, and the corresponding height velocity was calculated as the first derivative. Peak height velocity (PHV) age and magnitude were estimated from the velocity curves. Among stimulant-treated ADHD cases, we analyzed height Z scores at the beginning, at the end, and 24 months after the end of treatment. RESULTS: Neither ADHD itself nor treatment with stimulants was associated with differences in magnitude of PHV or final adult height. Among boys treated with stimulants, there was a positive correlation between duration of stimulant usage before PHV and age at PHV (r = 0.21, P = .01). There was no significant correlation between duration of treatment and change in height Z scores (r = -0.08 for beginning vs end change, r = 0.01 for end vs 24 months later change). Among the 59 ADHD cases treated for ≥3 years, there was a clinically insignificant decrease in mean Z score from beginning (0.48) to end (0.33) of treatment (P = .06). CONCLUSIONS: Our findings suggest that ADHD treatment with stimulant medication is not associated with differences in adult height or significant changes in growth.
Authors: Slavica K Katusic; William J Barbaresi; Robert C Colligan; Amy L Weaver; Cynthia L Leibson; Steven J Jacobsen Journal: Ann Epidemiol Date: 2005-07 Impact factor: 3.797
Authors: William J Barbaresi; Slavica K Katusic; Robert C Colligan; Amy L Weaver; Steven J Jacobsen Journal: J Dev Behav Pediatr Date: 2007-08 Impact factor: 2.225
Authors: Stephen V Faraone; Joseph Biederman; Christopher P Morley; Thomas J Spencer Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-09 Impact factor: 8.829
Authors: Joseph Biederman; Michael C Monuteaux; Thomas Spencer; Timothy E Wilens; Stephen V Faraone Journal: Pediatrics Date: 2009-07 Impact factor: 7.124
Authors: James Swanson; Laurence Greenhill; Tim Wigal; Scott Kollins; Annamarie Stehli; Mark Davies; Shirley Chuang; Benedetto Vitiello; Anne Skrobala; Kelly Posner; Howard Abikoff; Melvin Oatis; James McCRACKEN; James McGOUGH; Mark Riddle; Jaswinder Ghuman; Charles Cunningham; Sharon Wigal Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-11 Impact factor: 8.829
Authors: Thomas J Spencer; Stephen V Faraone; Joseph Biederman; Marc Lerner; Kimberly M Cooper; Brenda Zimmerman Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-05 Impact factor: 8.829
Authors: James M Swanson; Glen R Elliott; Laurence L Greenhill; Timothy Wigal; L Eugene Arnold; Benedetto Vitiello; Lily Hechtman; Jeffery N Epstein; William E Pelham; Howard B Abikoff; Jeffrey H Newcorn; Brooke S G Molina; Stephen P Hinshaw; Karen C Wells; Betsy Hoza; Peter S Jensen; Robert D Gibbons; Kwan Hur; Annamarie Stehli; Mark Davies; John S March; C Keith Conners; Mark Caron; Nora D Volkow Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-08 Impact factor: 8.829
Authors: William J Barbaresi; Slavica K Katusic; Robert C Colligan; Amy L Weaver; Cynthia L Leibson; Steven J Jacobsen Journal: J Dev Behav Pediatr Date: 2006-02 Impact factor: 2.225
Authors: Chadi A Calarge; James A Mills; Lefkothea Karaviti; Antonio L Teixeira; Babette S Zemel; Jose M Garcia Journal: J Pediatr Date: 2018-06-27 Impact factor: 4.406
Authors: Laurence L Greenhill; James M Swanson; Lily Hechtman; James Waxmonsky; L Eugene Arnold; Brooke S G Molina; Stephen P Hinshaw; Peter S Jensen; Howard B Abikoff; Timothy Wigal; Annamarie Stehli; Andrea Howard; Michael Hermanussen; Tomasz Hanć Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-08-15 Impact factor: 8.829
Authors: James M Swanson; L Eugene Arnold; Brooke S G Molina; Margaret H Sibley; Lily T Hechtman; Stephen P Hinshaw; Howard B Abikoff; Annamarie Stehli; Elizabeth B Owens; John T Mitchell; Quyen Nichols; Andrea Howard; Laurence L Greenhill; Betsy Hoza; Jeffrey H Newcorn; Peter S Jensen; Benedetto Vitiello; Timothy Wigal; Jeffery N Epstein; Leanne Tamm; Kimberly D Lakes; James Waxmonsky; Marc Lerner; Joy Etcovitch; Desiree W Murray; Maximilian Muenke; Maria T Acosta; Mauricio Arcos-Burgos; William E Pelham; Helena C Kraemer Journal: J Child Psychol Psychiatry Date: 2017-03-10 Impact factor: 8.982